Non-arteritic anterior ischemic optic neuropathy, known as NAION, is the most common cause of sudden optic nerve damage in adults over 50, and the nickname “eye stroke” captures the basic idea: blood flow to the optic nerve drops abruptly, and nerve tissue dies. The overall incidence runs about 4 per 100,000 people per year, but that figure roughly triples among people 50 and older.1PubMed. Reexamining the Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: A Rochester Epidemiology Project Study Unlike a brain stroke, where there are clot-busting drugs and emergency protocols, NAION has no proven acute treatment, which makes understanding its causes and risk factors all the more important.
What Happens Inside the Optic Nerve
The optic nerve carries visual signals from the retina to the brain. Its front portion, the optic nerve head, gets its blood supply from tiny branches of an artery behind the eye. In NAION, that blood supply is disrupted just enough to starve the nerve tissue. The result is swelling of the optic disc followed by permanent damage to some of the nerve fibers.
A key piece of the puzzle is anatomy. Some people are born with an optic disc that has very little empty space in its center, sometimes called a “disc at risk.” One study found that having this crowded disc anatomy carried the highest odds of developing NAION compared to any other single risk factor.2PubMed Central. Risk Factors for Non-arteritic Anterior Ischaemic Optic Neuropathy in a Korean Population Optical coherence tomography imaging has confirmed that the tissue in front of the nerve’s structural plate is thicker in NAION eyes and their unaffected fellow eyes than in eyes of people who never develop the condition, suggesting the anatomical predisposition exists before anything goes wrong.3Eye. Crowded optic nerve head evaluation with optical coherence tomography in anterior ischemic optic neuropathy You cannot change the anatomy you were born with, but knowing about it helps explain why NAION strikes certain people and not others.
Recognizing the Symptoms
NAION typically announces itself as sudden, painless vision loss in one eye. Many people notice it first thing in the morning. Vision may be blurry overall, or a specific chunk of the visual field may simply disappear. The most common pattern is loss of the lower half of vision in the affected eye, though the exact area varies.4PubMed. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination Color vision often dims, and the pupil in the affected eye reacts sluggishly to light compared to the other side.5Journal of Clinical Neuroscience. Non-arteritic anterior ischaemic optic neuropathy: A review and update
The lack of pain is a distinguishing feature. While some people report a vague ache around the eye, the dramatic pain sometimes seen with optic neuritis from multiple sclerosis is not part of the typical picture. If you wake up and part of your vision is simply gone, with no pain and no obvious external cause, that combination should prompt an urgent visit to an eye doctor.
Risk Factors That Stack Up
NAION is rarely caused by one thing. It tends to happen when several cardiovascular risk factors converge in someone with the vulnerable disc anatomy. Two large meta-analyses have identified the main culprits:
- Hypertension: raised the odds of NAION by roughly 30 to 50 percent across pooled studies.
- Diabetes: increased risk by about 50 to 70 percent.
- High cholesterol: associated with roughly double the odds in one meta-analysis, and about 40 percent higher risk in another.
- Coronary heart disease: roughly 70 percent higher risk.
- Male sex: about 67 percent higher risk.
These figures come from pooled analyses of dozens of studies, so the ranges reflect slightly different study populations and methods.6PubMed. Cardiometabolic factors and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis7Frontiers in Medicine. Risk Factors for Non-arteritic Anterior Ischemic Optic Neuropathy: A Large Scale Meta-Analysis Smoking also appears on the list. In a Korean population study, current smoking roughly tripled the odds.2PubMed Central. Risk Factors for Non-arteritic Anterior Ischaemic Optic Neuropathy in a Korean Population None of these risk factors are surprising for a vascular event. The pattern looks a lot like what you would expect for heart attack or brain stroke, which reinforces the “eye stroke” analogy.
The Sleep Connection
Obstructive sleep apnea has emerged as one of the strongest individual risk factors. In a meta-analysis, sleep apnea more than tripled the risk of NAION.7Frontiers in Medicine. Risk Factors for Non-arteritic Anterior Ischemic Optic Neuropathy: A Large Scale Meta-Analysis A small but striking study found that about 70 percent of NAION patients had sleep apnea, compared to about 18 percent of matched controls.8JAMA Ophthalmology. Association Between Sleep Apnea Syndrome and Nonarteritic Anterior Ischemic Optic Neuropathy One cohort study reported a relative risk of nearly 5 for sleep apnea among NAION patients, and that those with untreated sleep apnea had a 16 percent higher hazard of developing NAION compared to people without it.9PubMed Central. Obstructive sleep apnea and nonarteritic anterior ischemic optic neuropathy: evidence for an association
This connection to sleep ties into a broader observation: a significant proportion of NAION patients notice their vision loss upon waking. For years, researchers suspected that blood pressure dipping too low overnight was the final trigger. Early studies found an extreme overnight drop in blood pressure in NAION patients compared to normal values.10American Journal of Ophthalmology. Nocturnal Arterial Hypotension and Its Role in Optic Nerve Head and Ocular Ischemic Disorders That led to a common recommendation that people who have had NAION avoid taking blood pressure medications at bedtime.
The picture has gotten muddier, though. Later studies found that NAION patients actually had normal or even non-dipping blood pressure patterns overnight, and the cardiology literature increasingly shows that nighttime high blood pressure is itself harmful for the heart and brain.11PubMed. The Controversy of Chronotherapy: Emerging Evidence regarding Bedtime Dosing of Antihypertensive Medications in Non-Arteritic Anterior Ischemic Optic Neuropathy So the advice to avoid bedtime blood pressure medications is not as clear-cut as it once seemed. If you take blood pressure pills at night and are worried, talk to your doctor rather than stopping them on your own, since uncontrolled hypertension carries its own serious risks.
Getting the Diagnosis Right
NAION is largely a clinical diagnosis. There is no blood test that confirms it. An eye doctor will see a swollen optic disc in the acute phase, along with reduced vision and characteristic visual field loss. The more important diagnostic question is not “is this NAION?” but “is this the arteritic form instead?” Arteritic anterior ischemic optic neuropathy, caused by giant cell arteritis, is a medical emergency that requires immediate high-dose steroids to protect the other eye. It tends to hit people over 70, causes more severe vision loss, and often comes with headache, jaw pain, fatigue, and weight loss.
To tell the two apart, doctors check blood markers of inflammation. If those come back elevated, a biopsy of the temporal artery is recommended. NAION is essentially the diagnosis when giant cell arteritis has been ruled out and the clinical picture fits.12PubMed. Non-Arteritic Anterior Ischaemic Optic Neuropathy and Its Masquerades: A Comprehensive Diagnostic Review Other conditions that can mimic NAION include optic neuritis from demyelinating disease, autoimmune inflammation, hereditary optic neuropathies, and vascular abnormalities, so the diagnostic workup sometimes involves brain imaging and additional blood work.
Newer imaging tools are adding to the picture. Optical coherence tomography angiography can map the tiny blood vessels around the optic disc and show patterns of vascular loss that correlate with areas of visual field damage. In one study of NAION eyes, all showed diffuse loss of the small-vessel network around the disc, and about 57 percent also had a distinct wedge-shaped area of missing blood vessels that matched the field loss in more than 90 percent of cases.13PubMed Central. Optical coherence tomography angiography in acute unilateral nonarteritic anterior ischemic optic neuropathy: A comparison with the fellow eye and with eyes with papilledema This kind of imaging is not required for diagnosis, but it gives researchers a way to study the disease more precisely and may eventually help predict outcomes.
Why There Is No Proven Treatment
This is the hardest part of the NAION story. Despite decades of research, no therapy has been convincingly shown to restore lost vision. Steroids were a logical candidate because of the optic nerve swelling, but a meta-analysis of the available studies found that corticosteroids did not significantly improve visual acuity in NAION patients.14PubMed Central. Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis
In the 1990s, a major trial tested optic nerve sheath decompression surgery, based on the theory that cutting into the sheath around the nerve would relieve pressure and improve blood flow. The Ischemic Optic Neuropathy Decompression Trial was halted early because surgery was actually associated with worse outcomes than observation alone. A later analysis noted that surgical technique varied greatly among the participating centers, and that the procedure itself may have caused harm through prolonged pressure on the eye.15JAMA Ophthalmology. Lessons From the Ischemic Optic Neuropathy Decompression Trial: A Decade Later That trial remains a cautionary example. It also produced some of the best natural-history data we have on how NAION behaves without intervention.
Neuroprotective strategies are an active area of investigation. A systematic review found that in animal models of optic nerve ischemia, various neuroprotective compounds preserved significantly more nerve cells compared to controls. However, only three human studies met the review’s criteria, and the evidence was too thin to support clinical use.16PubMed Central. Neuroprotective Strategies for Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review Researchers are also exploring blood biomarkers that could predict outcomes. One recent study found that levels of a protein released by damaged nerve cells correlated with final visual acuity after an episode of optic neuropathy, which could eventually help identify patients who would benefit most from an intervention if one becomes available.17PubMed Central. Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies
What to Expect for Visual Recovery
The natural history of NAION offers some room for cautious hope. Data from the Ischemic Optic Neuropathy Decompression Trial showed that roughly 30 percent of patients experienced spontaneous improvement in visual sharpness within three months of onset, with no meaningful additional gains after that window.18PubMed Central. Restoring visual function in NAION by means of transpalpebral electrical stimulation: A case report That means most of the recovery that will happen tends to happen early.
A more recent study looking specifically at visual field recovery found that about a quarter of affected eyes showed meaningful improvement. Patients whose starting visual acuity and visual field scores were better at the initial visit were more likely to recover, while age, blood pressure, lipid levels, smoking, and treatment method did not predict who improved.19PLOS ONE. Prognostic factors associated with visual field recovery in non-arteritic anterior ischemic optic neuropathy In plain terms, if your starting vision was relatively preserved, you have a better chance of improvement. If the initial hit was severe, the odds of substantial recovery are lower.
The practical implication is that NAION often leaves permanent visual impairment, but rarely causes total blindness in the affected eye. Many people retain useful central vision or peripheral vision that allows them to continue daily activities. The severity varies enormously from person to person.
Protecting the Other Eye
One of the most common concerns after a first episode is whether the other eye will be hit. The answer is that it happens, but not inevitably. The Ischemic Optic Neuropathy Decompression Trial’s follow-up data reported that about 15 percent of patients developed NAION in the fellow eye over a median of about five years.20American Journal of Ophthalmology. The fellow eye in naion: report from the ischemic optic neuropathy decompression trial follow-up study Other studies have reported higher rates: one found 24 percent involvement over about three and a half years, and a Chinese cohort study found a 3-year cumulative rate of about 29 percent.21PubMed. Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy22Ophthalmic Research. Risk Factors for Fellow Eye Involvement in Patients with Nonarteritic Anterior Ischemic Optic Neuropathy
Diabetes appears to be the strongest predictor. The follow-up from the decompression trial found that diabetes and worse initial visual acuity in the first eye were the only factors significantly associated with fellow eye involvement.20American Journal of Ophthalmology. The fellow eye in naion: report from the ischemic optic neuropathy decompression trial follow-up study The Chinese cohort confirmed this, finding that diabetes tripled the hazard, and also reported that more severe visual field damage at the first episode and a higher sleep apnea severity score each independently increased the risk of fellow eye involvement.22Ophthalmic Research. Risk Factors for Fellow Eye Involvement in Patients with Nonarteritic Anterior Ischemic Optic Neuropathy
Whether aspirin protects the second eye has been studied but not settled. Two older studies suggested that daily aspirin reduced the rate of fellow eye involvement substantially, with one reporting that 325 mg daily cut second-eye involvement to 18 percent compared to 50 percent in patients who took no aspirin.23Eye. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy Another study found that aspirin taken at least twice a week reduced the relative risk by more than half.24Journal of Neuro-Ophthalmology. Aspirin Reduces the Incidence of Second Eye NAION These were not randomized controlled trials, so the evidence is suggestive rather than conclusive. Still, many neuro-ophthalmologists recommend low-dose aspirin after a first episode, especially when the patient has other cardiovascular risk factors that would make aspirin reasonable on its own merits.
NAION and Broader Cardiovascular Risk
An episode of NAION should be treated as a signal that the cardiovascular system is under stress. A nationwide study in Taiwan found an increased risk of stroke in patients with a history of NAION.25American Journal of Ophthalmology. Increased Risk of Stroke in Patients With Nonarteritic Anterior Ischemic Optic Neuropathy: A Nationwide Retrospective Cohort Study This makes sense given the shared risk-factor profile between the two conditions. If you have been diagnosed with NAION and have not had a thorough cardiovascular workup, request one. Getting blood pressure, blood sugar, and cholesterol under control is the single most productive step you can take, even though none of these interventions will undo the vision loss that has already occurred.
Sleep apnea screening deserves special emphasis. Given the strength of the association, many specialists now recommend a sleep study for anyone diagnosed with NAION, particularly if they snore, feel excessively tired during the day, or have a larger neck circumference. Treating sleep apnea with continuous positive airway pressure may reduce the risk to the fellow eye, though this has not been proven in a randomized trial.
Medications Under Scrutiny
Two classes of medication have drawn attention in connection with NAION. Phosphodiesterase type 5 inhibitors, used for erectile dysfunction, have been linked to NAION in case reports.26PubMed Central. Non-Arteritic Anterior Ischemic Optic Neuropathy Associated With the Use of Phosphodiesterase Type 5 Inhibitors: A Literature Review However, a review of the evidence concluded that outside of a couple of cases with strong rechallenge data, the link is weak and that these drugs are likely a rare cause of a common condition.27Journal of the Neurological Sciences. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: Cause or coincidence? The FDA added a warning label, and people who have already had NAION in one eye are generally advised to avoid these medications.
More recently, semaglutide, the active ingredient in several widely prescribed weight-loss and diabetes drugs, came under investigation after a 2024 study used matched patient records to assess whether semaglutide prescriptions were associated with NAION in patients with type 2 diabetes or obesity.28JAMA Ophthalmology. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide The study generated considerable media attention and prompted further research, though NAION remains uncommon in absolute terms. Anyone currently taking semaglutide should not stop it based on a single observational study; discussing individual risk with a doctor is more appropriate than reacting to headlines.
How Common Is NAION Around the World
Incidence and prevalence estimates vary by country and how studies are designed. In the United States, the age- and sex-adjusted incidence has been estimated at about 4 per 100,000 overall, rising to about 10 per 100,000 among people 50 and older, with a median age at diagnosis of 65.1PubMed. Reexamining the Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: A Rochester Epidemiology Project Study A nationwide South Korean study reported an incidence of about 11 per 100,000 person-years in those 40 and older, with prevalence peaking in the early 70s for men and the late 60s for women.29PubMed. Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study Taiwan reported a somewhat lower incidence of about 4 per 100,000 person-years.25American Journal of Ophthalmology. Increased Risk of Stroke in Patients With Nonarteritic Anterior Ischemic Optic Neuropathy: A Nationwide Retrospective Cohort Study Differences in how aggressively each country’s healthcare system captures diagnoses likely account for some of the spread. Men are affected somewhat more often than women in most studies, though the South Korean data showed the gap was relatively modest.
These numbers mean NAION is not vanishingly rare. In a country with hundreds of millions of adults over 50, thousands of new cases occur every year. Yet it is uncommon enough that many primary care physicians may see only a handful of cases in their career, which can contribute to delayed diagnosis. The condition occupies an awkward middle ground: too common to ignore, too uncommon for most doctors to encounter routinely.